Background: Mycoplasma genitalium is a sexually transmitted pathogen associated with non-gonococcal urethritis and cervicitis. Azithromycin regimens have been considered first-line treatment for M. genitalium infections, with fluoroquinolone regimens effective as second-line treatments. However, the proportion of M. genitalium harbouring macrolide or fluoroquinolone resistance-associated mutations has been increasing worldwide. This study was done to compare the genotypic macrolide and fluoroquinolone resistance of M. genitalium strains obtained from women attending a termination of pregnancy clinic five years apart. Methods: M. genitalium was detected by PCR in vaginal swab samples from 100 and 104 termination of pregnancy attendees at a tertiary hospital in Pretoria, South Africa during 2012 and 2016 respectively. Genes associated with macrolide and fluoroquinolone resistance in the M. genitalium isolates were sequenced and analysed. Results: The prevalence of M. genitalium was 6.0% (6/100) in 2012 and 7.7% (8/104) in 2016. No resistance-associated mutations were seen in the 2012 isolates. Among the 2016 M. genitalium isolates, two (25%) harboured a macrolide-associated resistance mutation and one (12.5%) a fluoroquinolone resistance-associated mutation in the parC gene.
Background
Mycoplasma genitalium is a sexually transmitted pathogen associated with non-gonococcal urethritis, cervicitis, and related upper genital tract conditions such as pelvic inflammatory disease and infertility.
1,2 M. genitalium is the smallest selfreplicating prokaryote, but despite its small size, it is capable of causing disease, evades host immune responses through antigenic variability, and develops resistance to antimicrobial agents. 3 Routine screening for M. genitalium is performed in only a few countries. As the organism cannot readily be cultured on standard laboratory media, detection relies on nucleic acid amplification tests. Although there are a few commercial tests available, there are still no assays approved by the FDA for routine diagnostic testing. 4 In most cases of sexually acquired urethritis and cervicitis, tests are only performed for Neisseria gonorrhoeae and Chlamydia trachomatis.
The treatment of M. genitalium infection, either individually or as part of syndromic management, differs globally. Although no genetic determinant such as tetM has been found in this mycoplasma, tetracyclines are not useful for in vivo eradication of M. genitalium, with reported cure rates of around 30%. 5, 6 The efficacy of doxycycline, used extensively to treat non-gonococcal urethritis and cervicitis in the past, is relatively poor for M. genitalium infection. Azithromycin has been the preferred treatment for several years in many countries.
As with other bacterial sexually transmitted infections (STIs), such as gonorrhoea, antimicrobial resistance poses a threat to the effective treatment of M. genitalium. Treatment failure due to the rapid emergence of macrolide resistance is now very common and widespread. 7 Where studies have shown that older fluoroquinolones such as ciprofloxacin and levofloxacin are less active against M. genitalium, moxifloxacin has been demonstrated to be effective in patients with macrolide-resistant strains of M. genitalium. 8 However, fluoroquinolone resistance, including resistance to moxifloxacin, has also been described. 8 In South Africa, the recommended management of urogenital infections is syndromic. The recommended seven-day course of doxycycline for genital discharge syndromes (i.e. male urethritis and vaginal discharge) was changed in 2015 to include singledose oral azithromycin only, with doxycycline no longer in the guidelines for use other than for penicillin allergy in syphilis and balanitis.
Mutations in specific genes may be associated with resistance to antimicrobial drugs. Resistance to macrolides was shown to be due to mutations occurring in region V of the 23S rRNA gene, 9 and fluoroquinolone resistance due to mutations in the gyrA and parC genes 10 of M. genitalium.
In our study, we compared the macrolide and fluoroquinolone resistance profiles of M. genitalium strains obtained from woman attending a termination of pregnancy clinic in 2012 with those attending in 2016.
Materials and methods

Patient samples and processing
Patients visiting the termination of pregnancy clinic (TOP) at the Dr George Mukhari Academic Hospital (DGMAH) in Pretoria, South Africa were recruited for the study. Consecutive consenting women were enrolled both in 2012 (August) and in 2016 (September). Both groups of patients had not received any antibiotic therapy in the preceding month and gave verbal consent for participation. After a general examination, vaginal swab specimens were collected by a clinician and delivered to the laboratory within 24 hours. DNA was extracted from the swabs using the ZR Genomic DNA TM -Tissue MiniPrep kit (Zymo Research Corp, Irvine, CA, USA) according to the manufacturer's instructions for biological liquids and cell suspensions.
Molecular assays
DNA from the ATCC M. genitalium G37 strain (33530D) was included in all PCR assays as positive control, and PCR grade water (Bioline) was used as negative control. The presence of M. genitalium was detected using conventional PCR as described previously. 11 The primers targeted a 281 bp region of the 140 kDa adhesion gene (MgPa) of M. genitalium.
Antimicrobial resistance genes were analysed in all M. genitalium positive isolates. Potential macrolide resistance was detected by amplifying and sequencing a unique 147 bp region of the V region of the 23S rRNA of M. genitalium. None of the 2012 isolates harboured the parC alterations associated with fluoroquinolone resistance, while one strain from 2016 had the G248T resistance-associated mutation (Ser→Ile 83) which has been previously described for M. genitalium. 12 One strain in 2012 and three strains in 2016 shared the same silent mutation (C234T) in the parC gene. Results are summarised in Table 1 .
Discussion
The prevalence of M. genitalium among women attending for TOP at DGMAH did not change much over the five years between the studies (6.0% vs. 7.7%). This was similar to the prevalence of vaginal M. genitalium (8.7% [52/601]) in women visiting primary health care clinics across the Mopani District of Limpopo province in 2015.
14 The M. genitalium prevalence patterns tend to differ between studies, with rates ranging from 0% to as high as 47.5% in different population samples. 15, 16 Data collected from various studies concerning the prevalence of M. genitalium infections are somewhat inconsistent and contradictory and this is mainly due to the heterogeneity in populations studied, sampling methods used, underlying risk factors for infection and clinical presentation (symptomatic or asymptomatic). 15 In a study at a TOP clinic in Denmark, M. genitalium was detected in less than 1% of the 102 participants 17 while the organism was detected in 22.4% of women recruited from an urban medical centre in Cincinnati, USA. 18 As our study was not done among patients with vaginal discharge syndrome but rather among women seeking termination of pregnancy, the prevalence and probably bacterial loads of M. genitalium were relatively low. A South African study conducted on women with vaginal discharge syndrome from Cape Town and Johannesburg reported a significantly higher M. genitalium prevalence among participants from Johannesburg than those from Cape Town (11.2% vs. 2.1%; p = 0.0066). Although doxycycline has been used to treat nongonococcal urethritis and cervicitis for many years, it has been shown to have poor efficacy against M. genitalium and isolates with reduced susceptibility have been reported. 5 The macrolide azithromycin is now preferred for the treatment of nongonococcal urethritis and related clinical syndromes. However, after the first report in 2006 of azithromycin resistance observed in M. genitalium isolates among Australian patients, 20 the efficacy of the drug in treating M. genitalium infections has decreased worldwide. 21 Resistance to macrolides is believed to be associated with point mutations occurring in region 5 (referred to as 'V region') of the 23S rRNA. Three mutations at positions 2058 and 2059 (E. coli numbering) have been reported. 9 In our study, none of the 2012 isolates harboured macrolide resistance-associated mutations, while two of the 2016 isolates (25.0%) had the A2059G mutation, which is associated with macrolide resistance. This was also the most commonly seen resistance-associated mutation reported from Australia. 12 Ours is the second report of macrolide resistance in South Africa. Macrolide resistance-associated mutations were previously reported in 4/41 (9.8%) in M. genitalium-positive specimens collected from women attending primary health care clinics in the Limpopo province of rural South Africa.
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14 Contrary to our study, all their mutated specimens harboured the A2058G mutation.
The presence of macrolide resistance is of concern, as the treatment guidelines issued by the South African Department of Health were changed in 2015, when doxycycline was replaced by a single dose of azithromycin for the treatment of male urethritis and vaginal discharge syndromes. Although the prevalence of M. genitalium among the patients in our study was similar over the five-year period, macrolide resistance increased. This trend is observed in many countries, with the proportion of cases of M. genitalium with these mutations increasing in recent years. Data from Sweden showed the proportion of infections with a mutation increasing from 0% in 2006 to 14% in 2010, and 21% in 2011. 22 In Japan an increase from 0% in 2011 and 2012 to 29% in 2013 was reported 23 and in Australia an increase from about 20% between 2007 and 2009 to 36% between 2012 and 2013 was shown. 24 It is believed that the continued use of azithromycin 1 g therapy is driving the increase in macrolide antimicrobial resistance as a result of frequent selection of resistant genotypes. 21 This has led some investigators to use an extended dose of azithromycin, in the belief that it may be less likely to induce resistance than a single 1 g dose. 8, 25 Following treatment failure by macrolides, patients with macrolide-resistant strains of M. genitalium are usually treated with fluoroquinolones, particularly moxifloxacin. 7 This fourthgeneration quinolone drug is bactericidal and generally well tolerated. In our study, none of the strains harboured mutations in the gyrA gene. One M. genitalium isolate from 2016 harboured a fluoroquinolone resistance-associated mutation in the parC gene, which is the first reported in South Africa. This G248T mutation (Ser→Ile 80) is among those that are known to be associated with fluoroquinolone resistance in M. genitalium and other closely related organisms. 13, 26 This mutation was common in M. genitalium isolates from patients attending sexual health clinics in Sydney, Australia, 12 as well as among Japanese men with male urethritis syndrome 23 and patients from France. 27 Although we did not perform susceptibility testing to confirm phenotypic resistance, based on previous studies it is likely that the mutation observed in our isolate will contribute to moxifloxacin resistance. 13 One strain in 2012 and three strains in 2016 shared the same silent mutation (C234T) in the parC gene of M. genitalium. This mutation was also commonly found among isolates in Japan, but the significance of this mutation is unknown. 13, 26 Resistance of M. genitalium to macrolides and fluoroquinolones in our study showed that in South Africa a similar trend is observed as reported for the Asia-Pacific region where escalating resistance to azithromycin and moxifloxacin for M. genitalium has been seen. Analysing 140 infections, combined macrolide/fluoroquinoloneresistant mutations were found in 8.6% of specimens, for which recommended therapies would be ineffective. 28 Limitations of this study include the small numbers of M. genitalium isolates obtained during this period that could be tested, and the absence of a clinical history from participants, especially on the treatment for genital discharge syndrome in the preceding period. More surveillance data over time are needed from both symptomatic and asymptomatic patients to describe trends in macrolide and fluoroquinolone resistance accurately.
In conclusion, macrolide-resistant M. genitalium was present in this population and fluoroquinolone resistance was seen for the first time. As the prevalence of M. genitalium and the associated number of antimicrobial resistance markers was low, this study still does not justify changing the South African treatment guidelines for symptomatic patients with M. genitalium. However, as data for M. genitalium are not widely available in South Africa this and future studies should pave the way towards improved antimicrobial surveillance in M. genitalium.
